Q4 2015 13F Holders as of 12/31/2015
-
Type / Class
-
Equity / Ordinary Shares
-
Shares outstanding
-
1.57B
-
Number of holders
-
47
-
Total 13F shares, excl. options
-
20.6M
-
Shares change
-
+6.94M
-
Total reported value, excl. options
-
$249M
-
Value change
-
+$83.8M
-
Number of buys
-
38
-
Number of sells
-
-13
-
Price
-
$12.06
Significant Holders of Adaptimmune Therapeutics PLC - Ordinary Shares (ADAP) as of Q4 2015
58 filings reported holding ADAP - Adaptimmune Therapeutics PLC - Ordinary Shares as of Q4 2015.
Adaptimmune Therapeutics PLC - Ordinary Shares (ADAP) has 47 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 20.6M shares
of 1.57B outstanding shares and own 1.31% of the company stock.
Largest 10 shareholders include FMR LLC (6.59M shares), Capital World Investors (4.6M shares), Foresite Capital Management II, LLC (1.76M shares), ADAGE CAPITAL PARTNERS GP LLC (850K shares), Rock Springs Capital Management LP (765K shares), FIL Ltd (754K shares), QVT Financial LP (666K shares), WELLINGTON MANAGEMENT GROUP LLP (580K shares), JENNISON ASSOCIATES LLC (487K shares), and ORBIMED ADVISORS LLC (439K shares).
This table shows the top 47 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.